Sage Therapeutics Receives EU Orphan Drug Designation for Huntington's Disease Treatment Candidate
Sage Therapeutics declared the European Medicines Agency granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington's disease. SAGE-718 is developing as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction. Multiple clinical studies are ongoing with SAGE-718 across several disease areas, including two placebo-controlled Phase II studies and a phase III open-label safety study in the lead indication of huntington's disease-related cognitive impairment, and additionally phase II placebo-controlled studies in mild co...
